Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Gadina

Showing results (1-10 of 121) with videos related to

Pageof 13
Sort By:
Seminars in Arthritis and Rheumatism|November 25, 2023
JAK inhibitors: Is specificity at all relevant?Massimo Gadina
The Journal of Investigative Dermatology. Symposium Proceedings|December 12, 2013
Janus kinases: an ideal target for the treatment of autoimmune diseasesMassimo Gadina
Current Opinion in Rheumatology|January 15, 2014
Advances in kinase inhibition: treating rheumatic diseases and beyondMassimo Gadina
Experimental Dermatology|October 18, 2013
Jakpot! New small molecules in autoimmune and inflammatory diseasesKamran Ghoreschi, Massimo Gadina
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|June 8, 2013
The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disordersYasuko Furumoto, Massimo Gadina
Science (New York, N.Y.)|June 20, 2024
JAKing up immunityMassimo Gadina, John J O'Shea
Science'S STKE : Signal Transduction Knowledge Environment|June 15, 2007
IL-33: a sheep in wolf's clothing?Massimo Gadina, Caroline A Jefferies
Molecular Interventions|June 24, 2004
Ubiquitination for activation: new directions in the NF-kappaB roadmapOonagh T Lynch, Massimo Gadina
Nature Medicine|December 8, 2009
Immune modulation: Turncoat regulatory T cellsMassimo Gadina, John J O'Shea
Nature Reviews. Rheumatology|January 10, 2019
Selective Janus kinase inhibitors come of ageJohn J O'Shea, Massimo Gadina
Pageof 13

Showing results (1-10 of 121) with videos related to

Sort By:
Pageof 13
Seminars in Arthritis and Rheumatism|November 25, 2023
JAK inhibitors: Is specificity at all relevant?Massimo Gadina
The Journal of Investigative Dermatology. Symposium Proceedings|December 12, 2013
Janus kinases: an ideal target for the treatment of autoimmune diseasesMassimo Gadina
Current Opinion in Rheumatology|January 15, 2014
Advances in kinase inhibition: treating rheumatic diseases and beyondMassimo Gadina
Experimental Dermatology|October 18, 2013
Jakpot! New small molecules in autoimmune and inflammatory diseasesKamran Ghoreschi, Massimo Gadina
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|June 8, 2013
The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disordersYasuko Furumoto, Massimo Gadina
Science (New York, N.Y.)|June 20, 2024
JAKing up immunityMassimo Gadina, John J O'Shea
Science'S STKE : Signal Transduction Knowledge Environment|June 15, 2007
IL-33: a sheep in wolf's clothing?Massimo Gadina, Caroline A Jefferies
Molecular Interventions|June 24, 2004
Ubiquitination for activation: new directions in the NF-kappaB roadmapOonagh T Lynch, Massimo Gadina
Nature Medicine|December 8, 2009
Immune modulation: Turncoat regulatory T cellsMassimo Gadina, John J O'Shea
Nature Reviews. Rheumatology|January 10, 2019
Selective Janus kinase inhibitors come of ageJohn J O'Shea, Massimo Gadina
Pageof 13